報價延遲最少15分鐘:2025/08/18 06:05 EDT
盤前時段
|
||||
|
12.75 
|
|
|
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
| 價值評估 |
|
盈利(現時/預測)
264.12/-16.50
|
|
企業價值
9.39M
|
| 資產負債 |
|
每股賬面淨值
0.52
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
8.01M
|
|
每股收益
4.38
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
報價延遲最少15分鐘：2025/08/18 06:05 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Reshape Lifesciences Inc is a medical device company focused on technologies to treat obesity and metabolic diseases. The company's current portfolio includes the LAP-BAND, an Adjustable Gastric Banding System, ReShapeCare virtual health coaching program, ReShape Market Place, including ReShape Optimize a supplemental multivitamin, the Obalon Balloon System, the first and only swallowable gas-filled balloon system, and the Diabetes Bloc-Stim Neuromodulation, a technology under development as a new treatment for type 2 diabetes mellitus. Geographically, the company operates in the United States, Australia, Europe, and the Rest of world, and the majority of its revenue is generated from the United States. |
